TW202338090A - 高效疫苗 - Google Patents

高效疫苗 Download PDF

Info

Publication number
TW202338090A
TW202338090A TW111148556A TW111148556A TW202338090A TW 202338090 A TW202338090 A TW 202338090A TW 111148556 A TW111148556 A TW 111148556A TW 111148556 A TW111148556 A TW 111148556A TW 202338090 A TW202338090 A TW 202338090A
Authority
TW
Taiwan
Prior art keywords
polynucleotide
protein
virus
derived
modified
Prior art date
Application number
TW111148556A
Other languages
English (en)
Chinese (zh)
Inventor
赤畑渉
強納森Ｆ 史密斯
傑弗瑞 李歐 亞歷山大
関田𨺓
Original Assignee
日商Ｖｌｐ醫療日本股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商Ｖｌｐ醫療日本股份有限公司 filed Critical 日商Ｖｌｐ醫療日本股份有限公司
Publication of TW202338090A publication Critical patent/TW202338090A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111148556A 2021-12-17 2022-12-16 高效疫苗 TW202338090A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163265634P 2021-12-17 2021-12-17
US63/265,634 2021-12-17
US202263393400P 2022-07-29 2022-07-29
US63/393,400 2022-07-29

Publications (1)

Publication Number Publication Date
TW202338090A true TW202338090A (zh) 2023-10-01

Family

ID=86774453

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111148556A TW202338090A (zh) 2021-12-17 2022-12-16 高效疫苗

Country Status (5)

Country Link
US (1) US20230201333A1 (enExample)
EP (1) EP4448770A4 (enExample)
JP (1) JP2024545253A (enExample)
TW (1) TW202338090A (enExample)
WO (1) WO2023113016A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025121971A1 (ko) * 2023-12-07 2025-06-12 기초과학연구원 자가 증폭 rna를 포함하는 바이러스 유사 입자 제조를 위한 알파 바이러스 기반 벡터 시스템
WO2025263616A1 (en) * 2024-06-21 2025-12-26 Vlp Therapeutics Japan, Inc. Efficient vaccine
US20260000702A1 (en) 2024-06-26 2026-01-01 Flagship Pioneering Innovations Vii, Llc Therapeutic circular dna forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327835C (en) * 1998-04-08 2010-09-21 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US20030040498A1 (en) * 2001-03-14 2003-02-27 Ansardi David Calvert Oncolytic RNA replicons
US20090104226A1 (en) * 2004-05-21 2009-04-23 Novartis Vaccines And Diagnostics Inc. Alphavirus Vectors for Respiratory Pathogen Vaccines
EP2451475A2 (en) * 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
KR102823029B1 (ko) * 2017-12-20 2025-06-20 브이엘피 테라퓨틱스 인코포레이티드 알파바이러스 레플리콘 입자
EP4103228A1 (en) * 2020-02-13 2022-12-21 Institut Pasteur Nucleic acid vaccine against the sars-cov-2 coronavirus
TWI891771B (zh) * 2020-04-17 2025-08-01 美商Ｖｌｐ醫療股份有限公司 冠狀病毒疫苗
EP4168042A1 (en) * 2020-06-19 2023-04-26 Ziphius Vaccines Self-amplifying sars-cov-2 rna vaccine
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
CN111961138B (zh) * 2020-10-20 2021-03-30 苏州茂行生物科技有限公司 疫苗融合蛋白

Also Published As

Publication number Publication date
JP2024545253A (ja) 2024-12-05
EP4448770A1 (en) 2024-10-23
US20230201333A1 (en) 2023-06-29
WO2023113016A1 (en) 2023-06-22
EP4448770A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
TWI891771B (zh) 冠狀病毒疫苗
WO2023234300A1 (en) Modified vaccine design developments
JP7788787B2 (ja) 遺伝子発現増強のための組成物および方法
US20180000912A1 (en) Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
US20230201333A1 (en) Efficient vaccine
JP2023534900A (ja) 自己増幅ｓａｒｓ－ｃｏｖ－２ｒｎａワクチン
JP2023520354A (ja) コロナウイルスワクチン
CN115927467A (zh) 用于多功能和有效的基因表达的rna复制子
TWI908704B (zh) α病毒複製子顆粒
US12134777B2 (en) Alphavirus replicon vector and immunotherapy by administering same
AU2018333530A1 (en) RNA replicon for expressing a T cell receptor or an artificial T cell receptor
US12097257B2 (en) Induction and enhancement of antitumor immunity involving Sindbis virus vectors expressing immune checkpoint proteins
US20240335528A1 (en) Efficient vaccine
WO2025263616A1 (en) Efficient vaccine
US20220062439A1 (en) Localized administration of rna molecules for therapy
CN118922546A (zh) 有效疫苗
BR112022021828B1 (pt) Vetor replicon de alfavírus imunologicamente ativo, composição e vacina